false
0001841330
0001841330
2024-09-26
2024-09-26
0001841330
KTTA:CommonStockParValue0.0001PerShareMember
2024-09-26
2024-09-26
0001841330
KTTA:WarrantsToPurchaseSharesOfCommonStockParValue0.0001PerShareMember
2024-09-26
2024-09-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 26, 2024
Pasithea
Therapeutics Corp.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40804 |
|
85-1591963 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1111 Lincoln Road, Suite 500
Miami Beach, Florida |
|
33139 |
(Address of principal executive office) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (786) 977-3380
N/A
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
KTTA |
|
The Nasdaq Capital Market |
Warrants to purchase shares of Common Stock, par value $0.0001 per share |
|
KTTAW |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD.
On September 26, 2024, Pasithea Therapeutics Corp.
issued a press release announcing positive initial safety, tolerability, pharmacokinetic, and preliminary efficacy data from its
Phase 1 clinical trial of PAS-004 in advanced cancer. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form
8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission,
and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PASITHEA THERAPEUTICS CORP. |
|
|
|
Date: September 26, 2024 |
By: |
/s/ Tiago Reis Marques |
|
Name: |
Tiago Reis Marques |
|
Title: |
Chief Executive Officer |
2
Exhibit 99.1
Pasithea
Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical
Trial of PAS-004 in Advanced Cancer
-- Single
patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on
drug into 6th dosing cycle --
-- No treatment-related
adverse events (TRAEs) or dose-limiting toxicities (DLTs) observed to date, including no rash or gastrointestinal (GI) AEs --
-- Systemic
exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities --
-- Half-life
of approximately 70 hours supports once-daily or less frequent oral dosing --
-- Distinctive
MEK inhibitor profile for the treatment of both NF1-related plexiform and cutaneous neurofibromas, cancer, and other opportunities --
MIAMI, FL., September 26, 2024 (GLOBE NEWSWIRE)
- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology
company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other
cancer indications, today announced safety, tolerability, pharmacokinetic (PK) and preliminary efficacy data from the first 2 cohorts
of patients (n=6) in its Phase 1 clinical trial of PAS-004, being conducted at four clinical sites in the United States.
The Phase 1 clinical trial is a multi-center,
open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary
efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients
who have failed BRAF/MEK inhibition (NCT06299839).
“We are very pleased to share the PK, safety,
and preliminary efficacy data from the 2 mg and 4 mg cohorts in our first-in-human Phase 1 clinical trial of PAS-004. We believe these
data demonstrate a PK and safety profile that differentiates PAS-004 as a next-generation MEK inhibitor. We have already achieved significant
PAS-004 exposures with a favorable safety profile and have not seen adverse side effects such as rash or GI toxicity, which are typical
for MEK inhibitors even at low doses. The long half-life at approximately 70 hours, and the ability to achieve a flat PK curve at steady-state,
aim to provide a constant target inhibition while avoiding peak plasma toxicities, which is a unique PK profile among MEK inhibitors used
for the treatment of Neurofibromatosis type 1 (NF1)” stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.
“In addition, we are encouraged to see early
potential signs of efficacy, with a heavily pre-treated patient with colorectal cancer showing prolonged stable disease. Colorectal cancer
is known to not provide a RECIST response when treated with single-agent MEK inhibitors. This patient has a BRAF K601E mutation, a mutational
status with no approved therapies. We are encouraged that this patient has been treated continuously into the 6th 28-day dosing
cycle with no toxicities or AEs observed. While still early in clinical development, we believe PAS-004 is showing early signs of differentiation,
indicating PAS-004 has the potential to outperform current MEK inhibitors in terms of safety, reduced administration frequency, and potentially
efficacy. Our goal is to provide a once-daily or less frequent dosing treatment with broader application, not only for NF1 but also for
other indications.”
Interim Phase 1 Results
Pharmacokinetics (PK) data for cohort 1 (2mg)
and cohort 2 (4mg) at day 1 and day 22 (steady state)
Dose Cohort |
Cmax (ng/mL)* |
Cmin (ng/mL)* |
AUC0-24 (ng*h/mL)* |
2 mg Day 1 |
4.91 (101.3) |
N/A |
86.3 (89.2) |
2 mg Day 22 |
16.2 (89.7) |
10.2 (119.4) |
354 (95.2) |
4 mg Day 1 |
6.36 (135.6) |
N/A |
100 (97.1) |
4 mg Day 22 |
61.3 (10.3) |
51.5 (20.8) |
1,390 (12.8) |
* Data are Geometric Mean (Geometric coefficient
of variation (CV)%), Cmax - highest concentration of a drug after a dose is given; Cmin - Lowest concentration of a drug after a dose
is given; AUC - area under the concentration-time curve and measures the total drug exposure (the extent) across time
Pharmacokinetics (PK)
| ● | Plasma exposure increased with an increase in dose and linear PK is observed |
| ● | Long half-life of approximately 70 hours will allow for once daily dosing or longer intervals |
| ● | Prolonged systemic exposure with minimal fluctuation in PAS-004 plasma concentration at steady state (Cmax/Cmin
ratio of 1.2) indicates a potential to achieve constant target inhibition |
At steady-state, drug levels peaked at about 5
hours with a geometric mean maximum concentration (Cmax) of 16.2 and 61.3 ng/mL for the 2 mg and 4 mg dose groups, respectively.
The mean elimination half-life was 67.9 hours supporting once-daily or less frequent oral dosing.
“PAS-004 has demonstrated distinct properties
that we believe are significant advantages for an oral MEK inhibitor. PAS-004 has a significantly longer half-life compared to early-generation
MEK inhibitors, particularly those used for the treatment of NF1, which have half-lives of less than 8 hours. The ability to achieve prolonged
plasma exposures, as reflected in stable plasma concentrations at steady state, may potentially allow PAS-004 to achieve efficacious doses
with a favorable safety profile.” stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.
Safety & Tolerability
| ● | No treatment-related adverse events (TRAEs) or dose limiting toxicities (DLTs) observed to date |
In the first 2 dosing cohorts (n=6), PAS-004 was
shown to be well-tolerated with a favorable safety profile with no drug-related dose interruptions, reductions or discontinuations. There
were no drug-related serious AEs (SAE) in any dose arm and no protocol-defined stopping criteria were met. Importantly, at the 2 and 4
mg dose levels no rash or skin toxicity, gastro-intestinal (GI) toxicity, or ocular toxicity have been observed to date.
The study independent Safety Review Committee
has completed its safety review of data from the second dose cohort of 4 mg and the Company has initiated cohort 3 dosing at an increased
dose of 8 mg in capsules and has filed a protocol amendment to increase dosing schedule.
PAS-004 Demonstrates a Differentiated MEK Inhibitor
Profile
Unlike first-generation MEK inhibitors for the treatment of NF1 that require twice-daily dosing (BID) and exhibit short half-lives (<8
hours), PAS-004 has the potential to achieve prolonged target inhibition due to its long half-life of approximately 70 hours with once-daily
dosing (QD). The PK profile shows consistent plasma levels at steady-state, as reflected by a low Cmax to Cmin ratio, potentially reducing
the risks for Cmax-related toxicity. These findings provide a compelling rationale for the advancement of PAS-004 into clinical trials
for both the treatment of cutaneous and plexiform neurofibromas in NF1, cancer and other MAPK-driven opportunities. The company expects
to provide additional trial updates on a periodic basis as the trial progresses.
About Pasithea Therapeutics Corp.
Pasithea is a biotechnology company focused on
the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced
team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities
for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis
(ALS).
Forward Looking Statements
This press release contains statements that constitute
“forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial and the safety,
tolerability, pharmacokinetic (PK) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical
fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other
statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s
current and future business strategies, product development, preclinical studies clinical studies, clinical and regulatory timelines,
market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive
in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the
Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements,
which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not
match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory
approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q
and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The
Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after
the date of this release, except as required by law.
Pasithea Therapeutics Contact
Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com
5
v3.24.3
Cover
|
Sep. 26, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 26, 2024
|
Entity File Number |
001-40804
|
Entity Registrant Name |
Pasithea
Therapeutics Corp.
|
Entity Central Index Key |
0001841330
|
Entity Tax Identification Number |
85-1591963
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1111 Lincoln Road
|
Entity Address, Address Line Two |
Suite 500
|
Entity Address, City or Town |
Miami Beach
|
Entity Address, State or Province |
FL
|
Entity Address, Postal Zip Code |
33139
|
City Area Code |
786
|
Local Phone Number |
977-3380
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
KTTA
|
Security Exchange Name |
NASDAQ
|
Warrants to purchase shares of Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Warrants to purchase shares of Common Stock, par value $0.0001 per share
|
Trading Symbol |
KTTAW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=KTTA_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=KTTA_WarrantsToPurchaseSharesOfCommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Pasithea Therapeutics (NASDAQ:KTTAW)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024